Dirk Winkler

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

Michael Hallek, Kirsten Fischer, Guenter Fingerle-Rowson et al. · The Lancet · 2010 · 1.9K citations

Hematological Malignancy, Lymphoid Neoplasia, Oncology +10

<i>TP53</i> Mutation and Survival in Chronic Lymphocytic Leukemia

Thorsten Zenz, Barbara Eichhorst, Raymonde Busch et al. · Journal of Clinical Oncology · 2010 · 587 citations · Full text

Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial

Stephan Stilgenbauer, Andrea Schnaiter, Peter Paschka et al. · Blood · 2014 · 502 citations

Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group

Kirsten Fischer, Paula Cramer, Raymonde Busch et al. · Journal of Clinical Oncology · 2012 · 429 citations · Full text

Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up

Thorsten Zenz, Alexander Kröber, Katrin Scherer et al. · Blood · 2008 · 381 citations · Full text